Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Pfizer's elranatamab (Elrexfio) outperformed three standard treatment regimens in patients with relapsed/refractory multiple myeloma, meeting the primary endpoint of progression-free survival (PFS) in the phase 3 MagnetisMM-32 trial. More than 75% of patients in the elranatamab arm had not experienced disease progression or death at the time of analysis, with an estimated 18-month PFS rate of 68%. Pfizer plans to submit the data to global health authorities.
Pfizer's elranatamab (Elrexfio), a BCMA-targeting bispecific antibody, has cleared a major hurdle in the treatment of relapsed/refractory multiple myeloma. In the phase 3 MagnetisMM-32 trial — enrolling 523 patients across 26 countries — elranatamab monotherapy delivered a statistically significant and clinically meaningful reduction in the risk of disease progression or death compared to three established standard-of-care regimens (EloPd, PVd, or Kd).
The results are especially notable given the patient population: those who had already received an anti-CD38 antibody (like daratumumab) and lenalidomide — two of the most commonly used therapies in myeloma — and had limited options remaining. Elranatamab's safety profile was consistent with prior data, with no new signals identified.
By the Numbers:
75% of elranatamab-treated patients had not progressed or died at interim analysis
Why it matters: As anti-CD38 and lenalidomide-based regimens move earlier in myeloma treatment, more patients are left with fewer options at relapse. Elranatamab's strong PFS benefit in this setting could support its use earlier in the treatment journey and reshape how relapsed myeloma is managed.
